{"entity":{"id":"nct07479485","kind":"trial","name":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","aka":[],"tldr":"A phase 1/2 trial of Pucotenlimab, Bevacizumab in hepatocellular carcinoma, run by Lepu Biopharma Co., Ltd., now recruiting.","summary":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) is a phase 1/2 interventional study registered as NCT07479485 by Lepu Biopharma Co., Ltd., with 160 participants planned, started 2026-04-08 and due to reach its primary completion in 2028-04. Interventions recorded: MRG006A, Pucotenlimab, Bevacizumab, PD1/VEGF antibody, TKI. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07479485","url":"https://clinicaltrials.gov/study/NCT07479485"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["pucotenlimab","bevacizumab"],"companies":["lepu-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07479485","phase":"1/2","setting":"An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma","sponsor":"Lepu Biopharma Co., Ltd.","enrolled":160,"outcomes":[]},"route":"/trials/nct07479485/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"pucotenlimab","kind":"drug","name":"Pucotenlimab","route":"/drugs/pucotenlimab/"}],"company":[{"id":"lepu-biopharma","kind":"company","name":"Lepu Biopharma","route":"/companies/lepu-biopharma/"}]}}